{"url_path":"/sec/tela/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1561921/0001104659-26-060234-index.html","accession_number":"0001104659-26-060234","cik":"0001561921","ticker":"TELA","issuer_name":"TELA Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1561921/0001104659-26-060234-index.html","primary_entity_key":"0001561921","primary_entity_name":"TELA Bio, Inc."},"word_count":1687,"has_tables":true,"body_markdown":"TELA Bio, Inc._March 31, 2026\n\nhttp://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent0001561921--12-312026Q1falsehttp://www.telabio.com/20260331#SecuredOvernightFinancingRateSofrOneMonthTermMember00001561921us-gaap:RetainedEarningsMember2026-03-310001561921us-gaap:AdditionalPaidInCapitalMember2026-03-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001561921us-gaap:RetainedEarningsMember2025-12-310001561921us-gaap:AdditionalPaidInCapitalMember2025-12-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001561921us-gaap:RetainedEarningsMember2025-03-310001561921us-gaap:AdditionalPaidInCapitalMember2025-03-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001561921us-gaap:RetainedEarningsMember2024-12-310001561921us-gaap:AdditionalPaidInCapitalMember2024-12-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001561921us-gaap:CommonStockMember2026-01-012026-03-310001561921us-gaap:CommonStockMember2026-03-310001561921us-gaap:CommonStockMember2025-12-310001561921us-gaap:CommonStockMember2025-03-310001561921us-gaap:CommonStockMember2024-12-310001561921tela:EquityIncentivePlan2019Member2026-04-082026-04-080001561921tela:ServiceBasedRestrictedStockUnitsMember2026-03-310001561921tela:ServiceBasedRestrictedStockUnitsMember2025-12-310001561921tela:PerformanceBasedRestrictedStockUnitsMember2025-12-310001561921tela:ServiceBasedRestrictedStockUnitsMember2026-01-012026-03-310001561921srt:MinimumMembertela:PerformanceBasedRestrictedStockUnitsMember2026-01-012026-03-310001561921srt:MaximumMembertela:PerformanceBasedRestrictedStockUnitsMember2026-01-012026-03-310001561921us-gaap:EmployeeStockOptionMembertela:EquityIncentivePlan2019Member2026-01-012026-03-310001561921tela:ServiceBasedRestrictedStockUnitMember2026-01-012026-03-310001561921us-gaap:NonUsMember2026-01-012026-03-310001561921tela:OvitexPrsMember2026-01-012026-03-310001561921tela:OvitexMember2026-01-012026-03-310001561921tela:OtherCustomersMember2026-01-012026-03-310001561921us-gaap:NonUsMember2025-01-012025-03-310001561921tela:OvitexPrsMember2025-01-012025-03-310001561921tela:OvitexMember2025-01-012025-03-310001561921tela:OtherCustomersMember2025-01-012025-03-310001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-03-012024-03-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001561921us-gaap:RetainedEarningsMember2026-01-012026-03-310001561921us-gaap:RetainedEarningsMember2025-01-012025-03-310001561921us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001561921us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001561921us-gaap:RestrictedStockUnitsRSUMember2026-03-310001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembertela:DisposalGroupTransactionMember2024-01-012024-03-310001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembertela:DisposalGroupTransactionMember2024-03-310001561921tela:PerceptiveCreditFacilityMember2026-03-310001561921tela:PerceptiveCreditFacilityMember2025-12-310001561921tela:MidcapTermLoansMember2022-05-260001561921tela:MidcapTermLoansMember2022-05-262022-05-260001561921tela:EquityIncentivePlan2019Member2026-03-310001561921tela:PrefundedCommonStockWarrantsMember2026-03-310001561921tela:CommonStockWarrantsIssuedWithCreditFacilityMember2026-03-310001561921tela:CommonStockWarrantsExpiringIn2028Member2026-03-310001561921tela:CommonStockWarrantsExpiringIn2027Member2026-03-310001561921tela:PerceptiveAdditionalWarrantsMembertela:PerceptiveCreditFacilityMember2025-11-140001561921tela:InitialLoanWarrantsMembertela:PerceptiveCreditFacilityMember2025-11-1400015619212024-12-310001561921us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2026-03-310001561921us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-12-3100015619212025-03-310001561921us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001561921us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001561921tela:CommonStockWarrantsMember2026-01-012026-03-310001561921tela:CommonStockWarrantsIssuedWithCreditFacilityMember2026-01-012026-03-310001561921us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001561921us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001561921tela:CommonStockWarrantsMember2025-01-012025-03-310001561921tela:PerceptiveCreditFacilityMember2026-01-012026-03-310001561921tela:MidcapTermLoansMember2025-01-012025-03-310001561921us-gaap:SellingAndMarketingExpenseMember2026-01-012026-03-310001561921us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001561921us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001561921us-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001561921us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001561921us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001561921us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001561921us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001561921tela:EquityDistributionAgreementMember2023-11-012026-03-310001561921us-gaap:EmployeeStockOptionMember2026-03-310001561921tela:PerformanceBasedRestrictedStockUnitsMember2026-03-310001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembertela:DisposalGroupTransactionMember2024-10-012026-03-310001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembertela:DisposalGroupTransactionMember2024-03-012024-03-310001561921tela:MimedxGroupIncMembertela:DisposalGroupTransactionMember2026-03-310001561921tela:MimedxGroupIncMembertela:DisposalGroupTransactionMember2024-03-310001561921tela:MimedxGroupIncMembertela:DisposalGroupTransactionMember2026-01-012026-03-310001561921tela:MimedxGroupIncMembertela:DisposalGroupTransactionMember2025-01-012025-03-310001561921tela:MimedxGroupIncMembersrt:MinimumMembertela:DisposalGroupTransactionMember2024-03-310001561921tela:MimedxGroupIncMembersrt:MaximumMembertela:DisposalGroupTransactionMember2024-03-310001561921srt:MinimumMember2025-11-140001561921srt:MaximumMember2025-11-140001561921tela:PerceptiveCreditFacilityMember2025-11-142025-11-140001561921tela:PerceptiveCreditFacilityMember2025-11-140001561921tela:EquityDistributionAgreementMember2023-11-300001561921tela:SingleReportableSegmentMember2026-01-012026-03-310001561921tela:SingleReportableSegmentMember2025-01-012025-03-310001561921tela:PerceptiveAdditionalWarrantsMembertela:PerceptiveCreditFacilityMember2026-01-012026-03-310001561921tela:CommonStockWarrantsIssuedWithCreditFacilityMember2026-01-012026-03-310001561921tela:CommonStockWarrantsExpiringIn2028Member2026-01-012026-03-310001561921tela:CommonStockWarrantsExpiringIn2027Member2026-01-012026-03-310001561921us-gaap:CommonStockMember2025-01-012025-03-3100015619212025-01-012025-03-3100015619212026-03-3100015619212025-12-3100015619212026-05-0500015619212026-01-012026-03-31xbrli:sharesiso4217:USDxbrli:puretela:itemiso4217:USDxbrli:sharestela:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES********SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****10-Q**\n\n**(Mark One)**\n\n​\n\n​\n\n**☒**\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the quarterly period ended****March 31, 2026**\n\n​\n\n**OR**\n\n​\n\n​\n\n​\n\n**☐**\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the transition period from ____ to ____**\n\n​\n\n**Commission File Number:****001-39130**\n\n​\n\n**TELA Bio, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n​\n\n​\n\n​\n\n​\n\n**Delaware**\n(State or other jurisdiction of\nincorporation or organization)\n\n  ​ ​ ​\n\n**45-5320061**\n\n(I.R.S. Employer\nIdentification No.) \n\n​\n\n​\n\n​\n\n**1 Great Valley Parkway, Suite 24**\n\n**Malvern****,****Pennsylvania******\n(Address of principal executive offices)\n\n​\n\n**19355**\n\n(Zip Code) \n\n​\n\n**(****484****)****320-2930******(Registrant’s telephone number, including area code)\n\n​\n\n**Not applicable**\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n​\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Title of each class**\n\n​\n\n**Trading Symbol**\n\n​\n\n**Name of each exchange on which registered**\n\nCommon Stock, $0.001 par value per share\n\n​\n\nTELA\n\n​\n\nThe Nasdaq Global Market\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ⌧ Yes ◻ No\n\n​\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ⌧ Yes ◻ No\n\n​\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\n​\n\n​\n\n​\n\n​\n\nLarge accelerated filer ◻\n\n​\n\n  ​ ​ ​\n\nAccelerated filer ◻\n\n​\n\n​\n\n​\n\nSmaller reporting company ☒ \n\nNon-accelerated filer ⌧ \n\n​\n\n​\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻\n\n​\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧\n\n​\n\nAs of May 5, 2026, the registrant had 44,766,146 shares of Common Stock, $0.001 par value per share, outstanding.\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nTABLE OF CONTENTS\n\n​\n\n​\n\n​\n\n​\n\n[**PART I FINANCIAL INFORMATION**](#FINANCIALINFORMATION_212102)\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1FinancialStatements_179801)\n\n[Financial Statements](#Item1FinancialStatements_179801)\n\n4\n\n​\n\n​\n\n​\n\n[Item 2.](#Item2MANAGEMENTSDISCUSSIONANDANALYSIS_96)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2MANAGEMENTSDISCUSSIONANDANALYSIS_96)\n\n19\n\n​\n\n​\n\n​\n\n[Item 3.](#Item3_Quant)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#Item3_Quant)\n\n30\n\n​\n\n​\n\n​\n\n[Item 4.](#Item4_Controls)\n\n[Controls and Procedures](#Item4_Controls)\n\n30\n\n​\n\n​\n\n​\n\n[**PART II OTHER INFORMATION**](#Part_II)\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1_Legal_Pro)\n\n[Legal Proceedings](#Item1_Legal_Pro)\n\n31\n\n​\n\n​\n\n​\n\n[Item 1A.](#Item1A_Risk)\n\n[Risk Factors](#Item1A_Risk)\n\n31\n\n​\n\n​\n\n​\n\n[Item 2.](#Item2_Unreg_Sales_Equity)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#Item2_Unreg_Sales_Equity)\n\n31\n\n​\n\n​\n\n​\n\n[Item 3.](#Item3_Defaults_Upon)\n\n[Defaults Upon Senior Securities](#Item3_Defaults_Upon)\n\n31\n\n​\n\n​\n\n​\n\n[Item 4.](#Item4_Mine_Safety)\n\n[Mine Safety Disclosures](#Item4_Mine_Safety)\n\n31\n\n​\n\n​\n\n​\n\n[Item 5.](#Item5_Other_Info)\n\n[Other Information](#Item5_Other_Info)\n\n31\n\n​\n\n​\n\n​\n\n[Item 6.](#Item6_Exhibits)\n\n[Exhibits](#Item6_Exhibits)\n\n32\n\n​\n\n​\n\n​\n\n​\n\n[Signatures](#Signatures)\n\n33\n\n​\n\n​\n\n​\n\n​\n\n1\n\n[Table of Contents](#TOC)\n\n​\n\n**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**\n\n​\n\nThis Quarterly Report on Form 10-Q (this “Quarterly Report”) and the documents incorporated by reference herein contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, we may, through our officers and other authorized representatives, make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our communications with our stockholders.\n\n​\n\nForward-looking statements are neither statements of historical facts nor assurances of future performance, but instead discuss the future of our business, operations, future financial performance, future financial condition, plans, anticipated growth strategies, anticipated or perceived trends in our business, the industry in which we operate or the broader economy, and other objectives of management. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “positioned,” “potential,” “seek,” “should,” “target,” “will,” “would,” the negative of such terms, and other similar expressions although not all forward-looking statements contain these identifying words.\n\n​\n\nYou should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:\n\n​\n\n●estimates regarding future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing;\n\n●our ability to maintain the listing of our common stock on the Nasdaq Global Market (“Nasdaq”);\n\n●the commercial success and degree of market acceptance of our products;\n\n●the introduction of new products or product enhancements by us or others in our industry, including new products which may be perceived to negatively impact the demand for our products now or in the future;\n\n●our ability to expand, manage and maintain our direct sales and marketing organization and to market and sell our products in the United States (“U.S.”) and Europe;\n\n●the performance of our exclusive contract manufacturer for our OviTex and OviTex PRS products, Aroa Biosurgery Ltd. (“Aroa”), in connection with the supply of product and in the development of additional products and product configurations within these products;\n\n●our ability to maintain our supply chain integrity and expand our supply chain to manage increased demand for our products;\n\n●our ability to compete successfully with larger competitors in our highly competitive industry;\n\n●our ability to achieve and maintain adequate levels of coverage or reimbursement for our current products and any future products we may seek to commercialize;\n\n●our ability to enhance our products, expand our indications and develop and commercialize additional products;\n\n●the development, regulatory approval, efficacy and commercialization of competing products;\n\n●our business model and strategic plans for our products, technologies and business, including our implementation thereof;\n\n●the size of the markets for our current and future products;\n\n●our ability to recruit and retain senior management and other highly qualified personnel;\n\n●our ability to obtain additional capital to finance our planned operations;\n\n●our ability to maintain regulatory approval for our products;\n\n●our ability to commercialize or obtain regulatory approvals for our future products, or the effect of delays in commercializing or obtaining regulatory approvals;\n\n●decreasing selling prices and pricing pressures;\n\n●regulatory developments in the U.S., including regulatory developments due to current or future changes in the U.S. presidential administration and European markets;\n\n●the potential impact of healthcare reform in the U.S., including the Inflation Reduction Act of 2022, and measures being taken worldwide designed to reduce healthcare costs;\n\n2\n\n[Table of Contents](#TOC)\n\n●any decrease in frequency of surgical procedures using our products, whether through outbreak of illness or disease, cybersecurity events impacting hospital operations, potential hospital closures, labor and hospital;\n\n●the occurrence of adverse safety events, restrictions on use with our products or product liability claims; and\n\nstaffing shortages, supply chain disruptions to critical surgical and hospital supplies, and any applicable adverse healthcare economic factors;\n\n●the volatility of capital markets and other adverse macroeconomic factors, including due to inflationary pressures, interest rate and currency rate fluctuations, economic slowdown or recession, banking instability, monetary policy changes, changes in trade policies (including tariffs and trade protection measures that have been or may in the future be imposed by the U.S. or other countries), geopolitical tensions or the outbreak of hostilities or war;\n\n●our ability to develop and maintain our corporate infrastructure, including our internal controls;\n\n●our ability to establish and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others;\n\n●our expectations regarding the use of proceeds from recent and any future financings, if any; and\n\n●other risks and uncertainties, including those listed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 (our “Annual Report”), our subsequent Quarterly Reports on Form 10-Q and the other documents we file with the Securities and Exchange Commission (the “SEC”).\n\n​\n\nThese forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all.\n\n​\n\nYou should refer to the section titled “Risk Factors” in our Annual Report, this Quarterly Report and any subsequent Quarterly Reports for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.\n\n​\n\n​\n\n​\n\n3\n\n[Table of Contents](#TOC)\n\nPART I — FINANCIAL INFORMATION"}